An update from Vaxcyte (PCVX) is now available.
Vaxcyte, Inc. revealed promising initial results from its study on VAX-31, a vaccine candidate for preventing invasive pneumococcal disease in adults over 50. The Phase 1/2 trial showed that the vaccine was safe, well-tolerated, and effective in generating an immune response, indicating potential for future use in combating this serious infection.
Learn more about PCVX stock on TipRanks’ Stock Analysis page.
